SCHEMBL4746023

SCHEMBL4746023

c1cnc2c(c1)-c1cccc3c1c-2cc1c2ccccc2c(-c2cccc4cccnc24)cc31

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.41
TSHR P16473 3/20 0.41
HIF1A Q16665 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
CCR1 P32246 5/20 0.41
CCR8 P51685 5/20 0.41
LMNA P02545 3/20 0.41
CCR5 P51681 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MMP2 P08253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13320348 0.90 L3MBTL1 (0.53) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4746267 0.90 ALDH1A1 (0.42) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4745832 0.89 ALDH1A1 (0.56) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4745841 0.89 ALDH1A1 (0.44) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4746392 0.88 ALDH1A1 (0.41) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4745930 0.87 ALDH1A1 (0.46) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4746454 0.87 ALDH1A1 (0.40) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4746407 0.87 PTPRC (0.40) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4745978 0.87 ALDH1A1 (0.47) L3MBTL1TSHRHIF1AALDH1A1HSD17B10
SCHEMBL4746158 0.86 ALDH1A1 (0.36) L3MBTL1TSHRHIF1AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 L3MBTL1 1513/4885TSHR 3386/4885HIF1A 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.